| Mammaglobin-A DNA Vaccine for Metastatic Breast Cancer (NCT00807781) | Washington University School of Medicine | 2009-10-01 |
| A Study to Assess PV-10 Chemoablation of Cancer of the Liver (NCT00986661) | Provectus Biopharmaceuticals, Inc. | 2009-10-01 |
| Evaluation of the Safety and Efficacy of THL-P in Metastatic Breast Cancer (NCT00976365) | Taiwan THL Co.LTd. | 2009-10-01 |
| Efficacy Study of [F-18]RGD-K5 Positron Emission Tomography (PET) as a Tool to Monitor Response to an Anti-angiogenic Drug (NCT00988936) | Siemens Molecular Imaging | 2009-09-01 |
| A Study of Trastuzumab Emtansine, Paclitaxel, and Pertuzumab in Patients With HER2-Positive, Locally Advanced or Metastatic Breast Cancer (NCT00951665) | Genentech, Inc. | 2009-08-01 |
| Trial to Evaluate the Therapeutic Benefit of Fulvestrant in Combination With ZACTIMA in Postmenopausal Women With Bone Predominant, Hormone Receptor Positive Metastatic Breast Cancer (NCT00811369) | Ontario Clinical Oncology Group (OCOG) | 2009-08-01 |
| Trastuzumab and Trastuzumab-MCC-DM1 Administered Intravenously and GDC-0941 Administered Orally to Patients With HER2-Positive Metastatic Breast Cancer Who Have Progressed on Previous Trastuzumab-Based Therapy (NCT00928330) | Genentech, Inc. | 2009-07-01 |
| Safety and Efficacy of TKI258 in FGFR1 Amplified and Non-amplified Metastatic HER2 Negative Breast Cancer (NCT00958971) | Novartis Pharmaceuticals | 2009-07-01 |
| Trial of Paclitaxel/Bevacizumab +/- Everolimus for Patients With HER2-Negative Metastatic Breast Cancer (NCT00915603) | SCRI Development Innovations, LLC | 2009-07-01 |
| Corrected QT Interval Effects of Trastuzumab Emtansine (T-DM1) in Patients With Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Locally Advanced or Metastatic Breast Cancer and the Safety and Tolerability of Combined T-DM1 and Pertuzumab in Patients With Early Disease Progression (NCT00943670) | Genentech, Inc. | 2009-07-01 |
| Dose-finding Study of BP-C1 in Patients With Stage IV Breast Cancer (NCT04298333) | Meabco A/S | 2009-06-27 |
| A Study of MM-111 in Patients With Advanced, Refractory Her2 Amplified, Heregulin Positive Cancers (NCT00911898) | Merrimack Pharmaceuticals | 2009-06-01 |
| Trial of Dasatinib Plus Ixabepilone in 2nd or 3rd Line Metastatic Breast Cancer (NCT00924352) | Accelerated Community Oncology Research Network | 2009-06-01 |
| Lapatinib Plus Caelyx in Patients With Advanced Metastatic Breast Cancer Following Failure of Trastuzumab Therapy (NCT00903656) | Arbeitsgemeinschaft medikamentoese Tumortherapie | 2009-05-01 |
| A Study of Trastuzumab Emtansine (Trastuzumab-MCC-DM1, T-DM1) in Combination With Pertuzumab Administered to Patients With Human Epidermal Growth Factor Receptor-2 (HER2)-Positive Locally Advanced or Metastatic Breast Cancer Who Have Previously Received Trastuzumab (NCT00875979) | Hoffmann-La Roche | 2009-05-01 |
| Phase I/II Trial of Sorafenib Plus Ixabepilone in HER2-Negative Metastatic Breast Cancer (NCT00825734) | SCRI Development Innovations, LLC | 2009-03-01 |
| Lapatinib in Women With Metastatic Breast Cancer Who Have Failed Prior Antihormone Therapy (NCT00759642) | University of Kansas Medical Center | 2009-03-01 |
| Non-Interventional Study With Vinorelbine ORAL in Advanced Non-Small Cell Lung Carcinoma(NSCLC) and Metastatic Breast Cancer (MBC) (NCT00890903) | Pierre Fabre Pharma GmbH | 2009-03-01 |
| Efficacy and Safety of IPI-504 With Trastuzumab Pretreated, Locally Advanced or Metastatic HER2 Positive Breast Cancer (NCT00817362) | Infinity Pharmaceuticals, Inc. | 2009-03-01 |
| Capecitabine and Bevacizumab ± Vinorelbine in Metastatic Breast Cancer (NCT00868634) | iOMEDICO AG | 2009-02-01 |
| A Phase 1b/2a, Open-Label, Multi-Center Study of Tivozanib (AV-951) in Combination With Paclitaxel in Subjects With Advanced or Metastatic Breast Cancer (NCT00717340) | AVEO Pharmaceuticals, Inc. | 2009-02-01 |
| Efficacy Study of Single Agent Trastuzumab or Lapatinib to Treat HER2-Overexpressing Breast Cancer (NCT00842998) | Azienda Ospedaliera Ordine Mauriziano di Torino | 2009-02-01 |
| A Survey of Breast Cancer Patients With Metastatic Bone Disease Receiving Oral Ibandronate (NCT02528747) | Hoffmann-La Roche | 2009-01-01 |
| Activated Allogeneic Lymphocytes for Induction Graft Versus Tumor Effect in Metastatic Solid Tumors (NCT00855452) | Hadassah Medical Organization | 2009-01-01 |
| A Trial l of Panobinostat Given in Combination With Trastuzumab and Paclitaxel in Adult Female Patients With HER2 Positive Metastatic Breast Cancer (NCT00788931) | Novartis Pharmaceuticals | 2008-12-01 |
| Lapatinib in Combination With Oral Vinorelbine for Metastatic Breast Cancer (NCT00912275) | National Taiwan University Hospital | 2008-11-24 |
| Trial of Ixabepilone in Patients With HER-2 Negative Metastatic Breast Cancer (HIT) (NCT00790894) | Hellenic Cooperative Oncology Group | 2008-11-01 |
| Lapatinib in Combination With Docetaxel in Patients With HER-2 Positive Advanced or Metastatic Breast Cancer (NCT01044485) | Centre Georges Francois Leclerc | 2008-11-01 |
| Community Oncology Setting Cost Analysis and Disease Outcomes of Taxane Use in Metastatic Breast Cancer (NCT00876070) | SCRI Development Innovations, LLC | 2008-11-01 |
| Study of Impact of Routine "Clinical Cancer Department/Supportive Care Department" Consultation on the Prescription of an Additional Line of Chemotherapy (NCT00905281) | Centre Leon Berard | 2008-11-01 |
| Lonafarnib in Metastatic Breast Cancer (NCT00773474) | George Sledge | 2008-10-01 |
| Faslodex Registry: Fulvestrant in Current Clinical Practice (NCT00735215) | AstraZeneca | 2008-10-01 |
| Phase I/II Study of AZD2281 Given in Combination With Paclitaxel in Metastatic Triple Negative Breast Cancer (NCT00707707) | AstraZeneca | 2008-09-15 |
| Phase I/II Trial of Letrozole and Sorafenib in Post-Menopausal Hormone-Receptor + Breast Cancer (NCT00634634) | Rutgers, The State University of New Jersey | 2008-08-11 |
| A Study of Trastuzumab-Mcc-DM1 Administered Intravenously to Patients With HER2-Positive Metastatic Breast Cancer (NCT00679211) | Genentech, Inc. | 2008-08-01 |
| A Study for Safety and Effectiveness of IMC-A12 by Itself or Combined With Antiestrogens to Treat Breast Cancer (NCT00728949) | Eli Lilly and Company | 2008-08-01 |
| Randomized Phase II Trial of Letrozole With or Without Dasatinib as First and Second-line Treatment for Hormone Receptor-positive, HER2-negative Post-menopausal Breast Cancer That is Unresectable, Locally Recurrent or Metastatic (NCT00696072) | Bristol-Myers Squibb | 2008-08-01 |
| Combination of Oral WX-671 Plus Capecitabine vs. Capecitabine Monotherapy in First-line Her2-negative Metastatic Breast Cancer (NCT00615940) | Heidelberg Pharma AG | 2008-07-01 |
| Phase 2 Study of ABT-869 in Combination With Paclitaxel Versus Paclitaxel Alone to Treat Metastatic Breast Cancer (NCT00645177) | AbbVie (prior sponsor, Abbott) | 2008-07-01 |
| Lapatinib and Circulating Tumor Cells in Breast Cancer (NCT00694252) | University Hospital of Crete | 2008-07-01 |
| Vinorelbine Oral Plus Capecitabine Combination In Metastatic Breast Cancer (NCT00706069) | Hellenic Oncology Research Group | 2008-06-01 |
| Randomized Phase II Study of Ixabepilone Alone and Ixabepilone Plus Cetuximab as First-Line Treatment for Female Subjects With Triple Negative Locally Advanced Non-resectable and/or Metastatic Breast Cancer (NCT00633464) | R-Pharm | 2008-06-01 |
| Phase II Trial of Doxil, Carboplatin, Bevacizumab in Triple Negative Untreated Metastatic Breast Cancer (NCT00608972) | Rutgers, The State University of New Jersey | 2008-05-16 |
| A Phase I Cancer Vaccine Study for Patients With Metastatic Breast Cancer (NCT00715832) | Southern Cancer Center | 2008-05-01 |
| Open Label Trial of Perifosine in Patients Currently Being Treated on Perifosine Trials in Solid Tumors or Multiple Myeloma (NCT00847366) | AEterna Zentaris | 2008-05-01 |
| 2-arm Trial of Paclitaxel Plus Bevacizumab vs. Capecitabine Plus Bevacizumab (NCT00600340) | Central European Cooperative Oncology Group | 2008-04-01 |
| ZK 230211 in Postmenopausal Woman With Metastatic Breast Cancer (NCT00555919) | Bayer | 2008-03-01 |
| Gemcitabine Plus Bevacizumab in Locally Recurrent or Metastatic Breast Cancer (NCT00623233) | Eli Lilly and Company | 2008-03-01 |
| Phase I/II Study of MK-0752 Followed by Docetaxel in Advanced or Metastatic Breast Cancer (NCT00645333) | University of Michigan Rogel Cancer Center | 2008-03-01 |
| A Study to Evaluate Pertuzumab + Trastuzumab + Docetaxel vs. Placebo + Trastuzumab + Docetaxel in Previously Untreated HER2-Positive Metastatic Breast Cancer (NCT00567190) | Genentech, Inc. | 2008-02-12 |
| Expressive Writing and Adjustment to Metastatic Breast Cancer (NCT00624156) | Memorial Sloan Kettering Cancer Center | 2008-02-01 |
| First Line Therapy for Patients With Metastatic Breast Cancer (NCT00456846) | Celgene | 2008-02-01 |
| A Phase II Combination of Trastuzumab and Ixabepilone Versus Trastuzumab and Docetaxel in Patients With Advanced and/or Metastatic Breast Cancer (NCT00490646) | R-Pharm | 2008-02-01 |
| Lapatinib and Temozolomide for the Treatment of Progressive Brain Disease in HER-2 Positive Breast Cancer (NCT00614978) | Jules Bordet Institute | 2008-01-01 |
| Phase II Study With the Trifunctional Antibody Ertumaxomab to Treat Metastatic Breast Cancer After Progression on Trastuzumab Therapy (NCT00522457) | Neovii Biotech | 2008-01-01 |
| Survival Endpoints in Women Treated for Metastatic Breast Cancer: Contribution of Real-life Databases (NCT03676257) | Institut Bergonié | 2008-01-01 |
| Evaluate the Relationship of Bone Remodeling Markers for Skeletal Complications in Metastatic Breast Cancer Patients (NCT00912938) | Korean Breast Cancer Study Group | 2007-12-01 |
| Overcoming Endocrine Resistance in Metastatic Breast Cancer (NCT02394496) | Consorzio Oncotech | 2007-11-01 |
| ABI-008 Trial in Patients With Metastatic Breast Cancer (NCT00531271) | Celgene | 2007-11-01 |
| PTC299 and Hormonal Agent for Treatment of Metastatic Breast Cancer (NCT00508586) | PTC Therapeutics | 2007-11-01 |
| Phase II Study of Ixabepilone in Metastatic Breast Cancer and Its Effects on the Ultrastructure of Neurons (NCT00627978) | Weill Medical College of Cornell University | 2007-11-01 |
| Phase IB/II Trial Combining Vinorelbine With Sorafenib as First-Line Treatment in Patients With Metastatic Breast Cancer (NCT00764972) | McGill University | 2007-10-01 |
| VinCaT: Vinorelbine, Carboplatin and Trastuzumab in Advanced Her-2 Positive Breast Cancer (NCT00431704) | National Cancer Institute, Naples | 2007-10-01 |
| A Phase II Study of Bevacizumab + Sorafenib in Metastatic Breast Cancer (NCT00632541) | Hoosier Cancer Research Network | 2007-10-01 |
| Phase II Trial of Capecitabine With Fulvestrant for Postmenopausal Women With Hormone Receptor Positive Metastatic Breast Cancer (NCT00534417) | Accelerated Community Oncology Research Network | 2007-10-01 |
| Gemcitabine and Cisplatin as First Line Combination Therapy in Patients With Triple-negative MBC (NCT00601159) | Fudan University | 2007-09-01 |
| Phase II Study of Carboplatin and Bevacizumab (Avastin) for ER Neg, PR Neg, and HER2/Neu Neg Metastatic Breast Cancer (NCT00517361) | University of Chicago | 2007-08-01 |
| Capecitabine (Xeloda) and Lapatinib (Tykerb) as First-line Therapy in HER2/Neu-positive Breast Cancer (NCT00496366) | Rutgers, The State University of New Jersey | 2007-07-23 |
| Open-Label,Non-Randomized Trial of Cisplatin Chemotherapy in BRCA1-Positive Metastatic Breast Cancer Patients (NCT01611727) | Pomeranian Medical University Szczecin | 2007-07-01 |
| A Study of Trastuzumab Emtansine (Trastuzumab-MCC-DM1) Administered Intravenously to Patients With Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Metastatic Breast Cancer (NCT00509769) | Genentech, Inc. | 2007-07-01 |
| Efficacy and Safety of Everolimus in Combination Therapy, in Patients With HER2-overexpressing Metastatic Breast Cancer (NCT00426556) | Novartis Pharmaceuticals | 2007-07-01 |
| ZD6474 (Zactima) and Metronomic Chemotherapy in Advanced Breast Cancer (NCT00496665) | Dana-Farber Cancer Institute | 2007-07-01 |
| A Continuation Study Using Sunitinib Malate For Patients Leaving Treatment On A Previous Sunitinib Study. (NCT00428220) | Pfizer | 2007-07-01 |
| Lapatinib in Combination With Capecitabine in Japanese Patients With Metastatic Breast Cancer (NCT00477464) | GlaxoSmithKline | 2007-06-01 |
| Phase Ⅱ Clinical Study of R435 (Bevacizumab) in Combination With Paclitaxel in Patients With Inoperable Metastatic Breast Cancer (NCT00467012) | Chugai Pharmaceutical | 2007-04-01 |
| Phase II Open-Label Trial of Tarceva in Women With Metastatic, Hormone- and HER2-Negative Breast Cancer (NCT00597597) | Rush University Medical Center | 2007-04-01 |
| A Phase I/II Clinical Trial Assessing Safety and Efficacy of BZL101 for Metastatic Breast Cancer (NCT00454532) | Bionovo | 2007-03-01 |
| A Study of Sunitinib in Combination With Bevacizumab and Paclitaxel in Previously Untreated Patients With Metastatic Breast Cancer (SABRE-B) (NCT00434356) | Genentech, Inc. | 2007-03-01 |
| Phase II Study With the Trifunctional Antibody Ertumaxomab to Treat Metastatic Breast Cancer Progressing After Endocrine Treatment (NCT00452140) | Neovii Biotech | 2007-03-01 |
| A Trial of 2 Schedules of Ixabepilone Plus Bevacizumab and Paclitaxel Plus Bevacizumab for Breast Cancer (NCT00370552) | R-Pharm | 2007-03-01 |
| Doxorubicin HCL Liposome Injection (DOXIL) in Combination With Abraxane in Patients With Metastatic Breast Cancer (NCT00442260) | West Virginia University | 2007-02-01 |
| VEGF Trap in Treating Patients With Metastatic Breast Cancer (NCT00369655) | National Cancer Institute (NCI) | 2007-01-01 |
| Therapy of Metastatic Breast Cancer With Paclitaxel and Liposomal Doxorubicin (NCT00691912) | Claudia Lorenz-Schlüter | 2006-12-01 |
| A Study of Biweekly Gemcitabine, Paclitaxel, and Avastin in Patients With Metastatic Breast Cancer (NCT00618826) | Barbara Ann Karmanos Cancer Institute | 2006-11-01 |
| Study of Larotaxel in Combination With Weekly Herceptin® in Patients With HER2 Positive Metastatic Breast Cancer (NCT00387907) | Sanofi | 2006-10-01 |
| Phase 2 Neoadjuvant Doxorubicin and Cyclophosphamide -> Docetaxel With Lapatinib in Stage II/III Her2Neu+ Breast Cancer (NCT00404066) | George Albert Fisher | 2006-10-01 |
| E7389 Versus Capecitabine in Patients With Locally Advanced or Metastatic Breast Cancer Previously Treated With Anthracyclines and Taxanes (NCT00337103) | Eisai Inc. | 2006-09-20 |
| Randomized, Double Blind Multicenter Phase II Study of Time to Progression on Fulvestrant in Combination With Erlotinib or Placebo in Hormone Receptor-Positive Metastatic Breast Cancer (MBC) Subjects Who Progressed on First Line Hormonal Therapy (NCT00570258) | University of Arkansas | 2006-09-01 |
| Study to Determine the Utility of FES-PET and FDG-PET in the Prediction of Response to Hormone Therapy in Women With Estrogen Positive Metastatic Breast Cancer (NCT00358098) | AHS Cancer Control Alberta | 2006-08-01 |
| Phase I Combination w/ Epirubicin (NCT00322374) | R-Pharm | 2006-08-01 |
| Phase II Trial of Bortezomib and Doxorubicin in Metastatic Breast Cancer (NCT00574236) | University of Wisconsin, Madison | 2006-08-01 |
| Phase I Study of Aprotinin in Advanced Breast Cancer (NCT00354900) | Dartmouth-Hitchcock Medical Center | 2006-07-01 |
| Safety Study of Combined Immunotherapy With Trastuzumab and Cetuximab in Patients With Metastatic Breast Cancer (NCT00367250) | Medical University of Vienna | 2006-07-01 |
| IMP321 Plus First-line Paclitaxel in Metastatic Breast Carcinoma (NCT00349934) | Immutep S.A.S. | 2006-07-01 |
| Tesmilifene in Combination With Docetaxel in the Treatment of Metastatic Breast Cancer (NCT00364195) | YM BioSciences | 2006-06-01 |
| ABI-007 In Combination With Bevacizumab in Women With Metastatic Breast Cancer (NCT00394082) | Celgene | 2006-06-01 |
| Combination Chemotherapy of Gemcitabine and Paclitaxel for Metastatic Breast Cancer (NCT00334802) | Eli Lilly and Company | 2006-06-01 |
| A Clinical Trial to Compare Efficacy and Tolerability of Fulvestrant 250mg, 250mg Plus 250mg Loading Regimen and 500mg (NCT00313170) | AstraZeneca | 2006-05-30 |
| Efficacy Study of Gemcitabine-Paclitaxel to Treat Metastatic Breast Cancer (NCT00316199) | Eli Lilly and Company | 2006-04-01 |
| A Study of Trastuzumab-MCC-DM1 Administered Intravenously to Patients With HER2-Positive Metastatic Breast Cancer Who Have Previously Received a Trastuzumab-Containing Regimen (NCT00932373) | Genentech, Inc. | 2006-04-01 |